Zoetis (ZTS) valuation
Zoetis P/E ratio history
Zoetis trades at 13.0 times its earnings over the last twelve months and 12.6 times the earnings analysts expect over the next twelve. At its last 10 fiscal year ends its P/E ranged from 20.9 (year to Dec 2025) to 57.2 (year to Dec 2021), with a median of 35.8.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $125.82 | $6.02 | 20.9 | 18.8 |
| Dec 31, 2024 | $162.93 | $5.47 | 29.8 | 26.0 |
| Dec 31, 2023 | $197.37 | $5.07 | 38.9 | 33.6 |
| Dec 31, 2022 | $146.55 | $4.49 | 32.6 | 27.7 |
| Dec 31, 2021 | $244.03 | $4.27 | 57.2 | 49.1 |
| Dec 31, 2020 | $165.50 | $3.42 | 48.4 | — |
| Dec 31, 2019 | $132.35 | $3.12 | 42.4 | — |
| Dec 31, 2018 | $85.54 | $2.93 | 29.2 | — |
| Dec 31, 2017 | $72.04 | $1.75 | 41.2 | — |
| Dec 31, 2016 | $53.53 | $1.65 | 32.4 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Zoetis valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| ZoetisZTS | $33.4B | 13.0 | 12.6 | 3.5 |
| ViatrisVTRS | $22.2B | — | 7.3 | 1.5 |
| Bristol Myers SquibbBMY | $128B | 13.8 | 9.5 | 2.6 |
| Corcept TherapeuticsCORT | $8.71B | 193.1 | 25.7 | 10.5 |
| PfizerPFE | $174B | 40.2 | 10.5 | 2.7 |
| Novo NordiskNVO | $178B | 9.9 | — | 3.5 |
| MerckMRK | $369B | 119.6 | 25.0 | 5.6 |
| Johnson & JohnsonJNJ | $658B | 41.5 | 23.8 | 6.6 |
| Eli LillyLLY | $1.33T | 46.0 | 31.0 | 15.4 |
| Peer median | 41.5 | 23.8 | 4.5 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ZTS financials · ZTS returns
No forecast, no recommendation. This page describes Zoetis from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.